—
RnRMarketResearch.com include Diabetic Nephropathy - Pipeline Review, H1 2017 is new Oncology report. Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.Diabetic Nephropathy Pipeline report has 42 Company Profiles, 61 Tables and 11 Figures, Spread across 200 Pages Report Available at http://www.rnrmarketresearch.com/diabetic-nephropathy-pipeline-review-h1-2017-market-report.html .
Diabetic Nephropathy Pipeline - Drug Profiles: 11-RVIVIT, A-717, APD-371, APX-115, ASP-8232, atesidorsen sodium, atrasentan hydrochloride, BI-703704, BL-5923, BLR-200, C-21, canagliflozin, CCX-140, cenicriviroc mesylate, cibinetide, corticotropin, CSL-346, Cyndacel-M, DM-299, DT-23552, DYN-12, emapticap pegol, esaxerenone, finerenone, GKT-136901 more..
Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.
Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=936577
Diabetic Nephropathy - Companies Involved in Therapeutics Development : AbbVie Inc, Allergan Plc, Antisense Therapeutics Ltd, Aptevo Therapeutics Inc, Araim Pharmaceuticals Inc, Arena Pharmaceuticals Inc, Astellas Pharma Inc, AstraZeneca Plc, Bayer AG, BLR Bio LLC, Boehringer Ingelheim GmbH, Cellmid Ltd, ChemoCentryx Inc, CSL Ltd, Daiichi Sankyo Company Ltd, DiaMedica Therapeutics Inc, Dynamis Therapeutics Inc, Galectin Therapeutics Inc, GenKyoTex SA, Gilead Sciences Inc, GNI Group Ltd, Islet Sciences Inc, Jenrin Discovery Inc, Johnson & Johnson, Mallinckrodt Plc, Mesoblast Ltd, Mitsubishi Tanabe Pharma Corp, MorphoSys AG, Novartis AG, Noxxon Pharma AG, Omeros Corp, PhiloGene Inc, PhytoHealth Corp, ProMetic Life Sciences Inc, RegenMedTX LLC, Serodus ASA, Teijin Pharma Ltd, Theravance Biopharma Inc, Variant Pharmaceuticals Inc, Vascular Pharmaceuticals Inc, Vicore Pharma AB, XORTX Pharma Corp
Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Discount Available at http://www.rnrmarketresearch.com/contacts/discount?rname=936577
The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 15, 6, 30, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
List of Figures
Number of Products under Development for Diabetic Nephropathy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
Related Report:
Diabetic Neuropathy - Pipeline Review, H1 2017 : Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. Key players are Achelios Therapeutics Inc, Angelini Group, Apollo Endosurgery Inc, Araim Pharmaceuticals Inc, Celgene Corp, Commence Bio Inc, Grunenthal GmbH, Kineta Inc, KPI Therapeutics Inc, Medifron DBT Co Ltd, Neuralstem Inc, NovaLead Pharma Pvt Ltd, Omeros Corp, Reata Pharmaceuticals Inc, Relief Therapeutics Holding AG, ViroMed Co Ltd.
About Us:
RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.
Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Organization: RnRMarketResearch.com
Website: http://www.rnrmarketresearch.com/diabetic-nephropathy-pipeline-review-h1-2017-market-report.html
Release ID: 210008
Google
RSS